HTL Biotechnology inaugurates a new production line dedicated to sterile Hyaluronic Acid
As part of National Biomanufacturing Day 2025, HTL Biotechnology inaugurates a new production line dedicated to Hyaluronic Acid.
Press releases
June 3, 2024
BIOPHTA 6.5 million Euros Seed Funding
Paris, June 3, 2024
BIOPHTA, a preclinical biotech company developing a game-changing technology for the treatment of eye diseases, has just closed a € 6.5 million Seed round to bring its patented technology to clinical development.
This funding round was led by leading European VCs – UI Investissement (via the Pertinence Invest 2 Fund, advised by Mérieux Equity Partners), Elaia and GO Capital – as well as one major ophthalmology player, Unither Pharmaceuticals and HTL Biotechnology, the global leader in production and development of pharma grade biopolymers.
To see our most recent news,
follow us on LinkedIn
Read more
news from us
-
Articles October 9, 2025HTL Biotechnology rallies for Pink October 2025
This October, HTL Biotechnology turned pink to support breast cancer prevention.
-
Articles September 19, 2025HTL Biotechnology wins the Responsible Care 2025 Award
HTL Biotechnology is the winner of the Responsible Care West Atlantic Trophy in the ‘Energy – Climate’ category for its project to reduce carbon emissions from distillation systems.
-
Articles September 13, 2025Looking Back at Our Presence at ESCRS 2025
The European Society of Cataract and Refractive Surgeons (ESCRS) is a unique opportunity each year to connect with our clients and partners while gaining insights into the key trends shaping the future of ophthalmology.